Get the Stockscreener App
4.41
2.32%
0.10
Foghorn Therapeutics Inc stock is traded at $4.41, with a volume of 114.20K.
It is up +2.32% in the last 24 hours and down -14.20% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.31
Open:
$4.33
24h Volume:
114.20K
Relative Volume:
0.76
Market Cap:
$245.17M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.8846
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+4.01%
1M Performance:
-14.20%
6M Performance:
-25.25%
1Y Performance:
+14.84%
1-Day Range:
$4.17
$4.5189
1-Week Range:
$4.14
$4.5189
52-Week Range:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.41 | 245.17M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Jane Street Group LLC - Defense World
Foghorn Therapeutics Sets 2025 Strategic Objectives - TipRanks
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 - The Manila Times
Foghorn Therapeutics Advances Cancer Drug Pipeline, Secures Runway into 2027 with $243.8M Cash - StockTitan
Barclays PLC Acquires 26,228 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLC - Defense World
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Expands By 6.8% - MarketBeat
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41% - Simply Wall St
Foghorn Therapeutics announces director resignation - Investing.com India
Foghorn Therapeutics announces director resignation By Investing.com - Investing.com Nigeria
Foghorn Therapeutics Board Member Resignation Announced - TipRanks
State Street Corp Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - Asianet Newsable
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
Jefferies Financial Group Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock Price - MarketBeat
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower - Benzinga
Foghorn Therapeutics Inc. Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - Marketscreener.com
Foghorn shifts focus from AML drug FHD-286 - Investing.com
Foghorn Therapeutics Ends Solo Development of FHD-286 - MarketWatch
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - The Manila Times
Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short - StockTitan
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) - MSN
This Foghorn Therapeutics Insider Reduced Their Stake By 13% - Simply Wall St
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - MSN
How the (FHTX) price action is used to our Advantage - Stock Traders Daily
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):